Pay in 4 interest-free payments of $5.16 Learn more
Ships within 48 hours · Estimated delivery Nov 7 - Nov 12
What GLP-1 Patent Estates Can Learn from the Sofosbuvir Litigation History The GLP-1 class semaglutide (Novo Nordisk), tirzepatide (Eli Lilly), retatrutide (Eli Lilly, Phase III), orforglipron (Eli Lilly) is generating patent portfolios that structurally resemble the sofosbuvir estate, with base compound patents surrounded by secondary filings on formulations, dosing devices, combination regimens, and cardiovascular or renal outcome indications supported by post-approval trial data
Diaz-Vivancos P, de Simone A, Kiddle G, Foyer CH
Most patients experience significant weight regain after stopping GLP-1 medications, with clinical trials showing regain of substantial weight within the first year
These are specifically from the Life Extension brand and focus much more on potential health benefits than other supplement companies that also sell diet products
1-2 Both these effects help with keeping blood sugar at a more balanced level
Meanwhile, Zepbound prescriptions soared 192% week-over-week to 22,335 as Eli Lilly ramps up the production of the drug in the first full month since its hard launch
US$ 25.07
US$ 20.92
US$ 23.34
US$ 29.84
US$ 26.47
